Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Titel:
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Auteur:
Gaudet, Daniel Kereiakes, Dean J. McKenney, James M. Roth, Eli M. Hanotin, Corinne Gipe, Daniel Du, Yunling Ferrand, Anne-Catherine Ginsberg, Henry N. Stein, Evan A.